1. Introduction {#sec1}
===============

Unfortunately, vaginitis remains a health issue in women. It has been estimated that there are around 10 million physician visits for vaginitis annually [@bib1]. However, biofilm formation is known as a major worldwide concern [@bib2]. Despite this, there are a vast majority of microbiology studies focusing on bacterial biofilm, but there is less consideration to medically important fungal biofilms. Among fungi, the genus *Candida*, especially *Candida albicans*, is responsible for around 15--20% of vaginitis cases in women [@bib3]. Studies have demonstrated that the majority of biofilm formation by *C. albicans* occurred in the oral cavities, environment, and vaginas of patients [@bib4].

New drug discovery could also be useful for the eradication of potent fungi in biofilm formation. Herbal medicines are defined as natural products, which are used in traditional medicine. The use of medicinal plants goes back 60,000 years ago [@bib5]. *Peganum harmala*, usually called Esfand, is a plant of the family of Nitrariaceae. It is applied as a traditional medicine for so many infections in Iran [@bib6]. Hence, the current study aimed to investigate the role of *P. harmala* in the inhibition of biofilm formation produced by *C. albicans*.

2. Materials and methods {#sec2}
========================

2.1. Organisms and identification {#sec2.1}
---------------------------------

*C. albicans* were collected from vulvovaginal candidacies women in the Ilam province in the west of Iran. The isolates were cultured on Sabouraud dextrose agar and then re-identified with a germ tube test [@bib7].

2.2. Cell culture {#sec2.2}
-----------------

The *P. harmala* extract was tested for its cytotoxicity effect on a Vero cell line. The percentage viability of the cell line was carried out by using the MTT assay (Sigma, United States).

2.3. Toxicity assay {#sec2.3}
-------------------

The cells were coated in a 96-well flat bottom plates at a density of 5,000--10,000 cells per well. Following this, the cells were treated with different concentrations of *P. harmala* ethanolic extract (1--100 μg/mL). After 24 hours, the MTT assay was applied to determine the toxicity concentration of *P. harmala.* The absorbance of the converted dye was measured at a wavelength of 570 nm with a background subtraction at 600 nm.

2.4. Biofilm formation assay {#sec2.4}
----------------------------

A 0.5 McFarland solution of *C. albicans* inoculated to 200 uL lurian broth (LB broth) in 96 micro plates for evaluation of biofilm formation. One colony from each *C. albicans* was applied to inoculate 5 mL LB broth. Then, the culture incubated for 24 hours at 35°C with aeration at 4 ×*g*. Then, 0.5 McFarland from each *C. albicans* was prepared. Following this, 200 μL of each *C. albicans* was transferred to a 96-well micro plate. The experiment was performed in duplicate. LB broth without *C. albicans* was considered as a negative control. The plates were incubated for 48 hours at 35^o^C.

2.5. Semiquantification of biofilm biomass {#sec2.5}
------------------------------------------

Biofilm biomass was quantified using a methodology described by Mowat et al [@bib8].

2.6. Analysis of biofilm formation {#sec2.6}
----------------------------------

The capacity of each strain to form a biofilm was compared with that of the confluent biofilm-forming *C. albicans* control by analyzing the absorbance of the crystal violet stain obtained for each biofilm. This allowed each isolate to be assigned a percentage value depending on the proportion of biofilm biomass it was able to establish after 48 hours in comparison with the control (taken as 100%).

Isolates were also divided into three groups depending on whether they formed fully established biofilms with 75% of the biomass of the positive control, moderately adherent biofilms with 25--75% biomass, or weak biofilms with 25% of the biomass of the positive control.

2.7. Antibiofilm formation activity determination of *P. harmala* {#sec2.7}
-----------------------------------------------------------------

Different concentrations (1--15 μg/mL) of *P. harmala* were applied on the positive biofilm formation strains. Then, the biofilm formation assay, as described above, was performed to evaluate the efficacy of *P. harmala* on biofilm formation by *C. albicans* isolates.

3. Results {#sec3}
==========

3.1. Biofilm formation in *C. albicans* {#sec3.1}
---------------------------------------

Our results demonstrated that among 100 yeasts responsible for vaginitis, 27% (*n* = 27) of them were *C. albicans*. Our analysis demonstrated that all types of biofilm formation were observed; while the most biofilm formation was observed as weak biofilms (37%, *n* = 10). The lowest biofilm formation was observed for both moderate and strong biofilm formation (each, 7.4%, *n* = 2). The remaining strains (48.2%, *n* = 13) showed no biofilm formation ([Figure 1](#fig1){ref-type="fig"}).

3.2. *P. harmala* as a candidate for inhibition of biofilm formation in *C. albicans* {#sec3.2}
-------------------------------------------------------------------------------------

The IC~50~ for *P. harmala* was 15 μg/mL. *P. harmala*, in a concentration of 12 μg/mL, easily inhibited biofilm formation on strong biofilm formation strains; while concentrations of 6 μg/mL and 10 μg/mL inhibited biofilm formation in weak and moderate biofilm formation *C. albicans* strains, respectively.

4. Discussion {#sec4}
=============

*C. albicans* is considered as a human pathogen and causes many infections ranging from severe to mild candidacies. Many factors are involved in the pathogenicity of *C. albicans*, including the production of extracellular enzymes, biofilm formation, and surface adherence [@bib9], [@bib10]. Also, *C. albicans* is settled in the vaginal cavity as a microbiota that causes vulvovaginal candidiasis. Our finding demonstrated that there is variation in biofilm formation in *C. albicans*, which is consistent with obtained results by Sherry et al [@bib11]. It seems to be necessary to investigate traditional herbs against pathogenic microorganisms. Our findings demonstrated the antibiofilm effectiveness of *P. harmala* against *C. albicans*. However, more investigations, including *in vivo* studies, are needed to study *P. harmala* as an antibiofilm in *C. albicans.*
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